The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Open accessAbstract
Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased tissue. Approximately 40% of patients do not respond to individual biologic therapies and 5–20% are refractory to all. In a biopsy-based, precision-medicine, randomized clinical trial in RA (R4RA; n = 164), patients with low/absent synovial B cell molecular signature had a lower response to rituximab (anti-CD20 monoclonal antibody) compared with that to tocilizumab (anti-IL6R monoclonal antibody) although the exact mechanisms of response/nonresponse remain to be established. Here, in-depth histological/molecular analyses of R4RA synovial biopsies identify humoral immune response gene signatures associated with response to rituximab and tocilizumab, and a stromal/fibroblast signature in patients refractory to all medications. Post-treatment changes in synovial gene expression and cell infiltration highlighted divergent effects of rituximab and tocilizumab relating to differing response/nonresponse mechanisms. Using ten-by-tenfold nested cross-validation, we developed machine learning algorithms predictive of response to rituximab (area under the curve (AUC) = 0.74), tocilizumab (AUC = 0.68) and, notably, multidrug resistance (AUC = 0.69). This study supports the notion that disease endotypes, driven by diverse molecular pathology pathways in the diseased tissue, determine diverse clinical and treatment–response phenotypes. It also highlights the importance of integration of molecular pathology signatures into clinical algorithms to optimize the future use of existing medications and inform the development of new drugs for refractory patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Salmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,685
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Self-citationSmolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710
Self-citationSmolen, J. S., Aletaha, D., Barton, A., Burmester, G. R., Emery, P., Firestein, G. S., Kavanaugh, A., McInnes, I. B., Solomon, D. H., Strand, V., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.1 · Cited by 2,445
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Cited by
Di Matteo, A., Bathon, J. M., & Emery, P. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01525-8 · Cited by 849
Rheumatoid Arthritis — Common Origins, Divergent Mechanisms
Gravallese, E. M., & Firestein, G. S. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2103726 · Cited by 752
The pathogenesis of rheumatoid arthritis
Alivernini, S., Firestein, G. S., & McInnes, I. B. (2022) · Immunity · doi:10.1016/j.immuni.2022.11.009 · Cited by 702
Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes
Zhang, F., Jonsson, A. H., Nathan, A., Millard, N., Curtis, M., Xiao, Q., Gutierrez-Arcelus, M., Apruzzese, W., Watts, G. F. M., Weisenfeld, D., et al. (2023) · Nature · doi:10.1038/s41586-023-06708-y · Cited by 443
Self-citationUsing explainable artificial intelligence to predict and forestall flare in rheumatoid arthritis
Alivernini, S., Cañete, J. D., Bacardit, J., & Kurowska-Stolarska, M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02818-w · Cited by 12
Self-citation
Metadata
- Authors
- Rivellese, F., Surace, A. E. A., Goldmann, K., Sciacca, E., Çubuk, C., Giorli, G., John, C. R., Nerviani, A., Fossati-Jimack, L., Thorborn, G., Ahmed, M., Prediletto, E., Church, S. E., Hudson, B. M., Warren, S. E., McKeigue, P. M., Humby, F., Bombardieri, M., Barnes, M. R., Lewis, M. J., Pitzalis, C., the R4RA collaborative group, Rivellese, F., Giorli, G., Nerviani, A., Fossati-Jimack, L., Thorborn, G., Humby, F., Bombardieri, M., Lewis, M. J., Durez, P., Buch, M. H., Rizvi, H., Mahto, A., Montecucco, C., Lauwerys, B., Ng, N., Ho, P., Romão, V. C., da Fonseca, J. E. C., Verschueren, P., Kelly, S., Sainaghi, P. P., Gendi, N., Dasgupta, B., Cauli, A., Reynolds, P., Cañete, J. D., Ramirez, J., Celis, R., Moots, R., Taylor, P. C., Edwards, C. J., Isaacs, J., Sasieni, P., Choy, E., Thompson, C., Bugatti, S., Bellan, M., Congia, M., Holroyd, C., Pratt, A., White, L., Warren, L., Peel, J., Hands, R., Hadfield, G., & Pitzalis, C.
- Venue
- Nature Medicine
- Published
- 2022-05-19
- Volume
- 28
- Issue
- 6
- Pages
- 1256-1268
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4280528160
- Cited by
- 294
- References
- 51
- FWCI
- 33.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. https://app.cochat.ai/papers/10.1038/s41591-022-01789-0
- The paper
- Rivellese, F., Surace, A. E. A., Goldmann, K., Sciacca, E., Çubuk, C., Giorli, G., John, C. R., Nerviani, A., Fossati-Jimack, L., Thorborn, G., Ahmed, M., Prediletto, E., Church, S. E., Hudson, B. M., Warren, S. E., McKeigue, P. M., Humby, F., Bombardieri, M., Barnes, M. R., . . . Pitzalis, C. (2022). Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01789-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.